Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously vaccinated with 3 primary doses of GSK 1024850A or Prevenar™ vaccine within the first 6 months of life and a booster dose of plain polysaccharide pneumococcal (Pneumovax 23™) vaccine at 11-14 months of age. Antibody persistence will also be assessed at approximately 4 years of age in children previously vaccinated with 3 doses of either GSK 1024850A or Prevenar™ vaccine followed by a booster dose of Pneumovax 23™. This protocol posting deals with objectives & outcome measures of the extension phase at year 4. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT 00307541). The objectives & outcome measures of the booster phase are presented in a separate protocol posting (NCT 00333450).

Official Title
-----------------
Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine

Conditions
-----------------
Infections, Streptococcal, Streptococcus Pneumoniae

Intervention / Treatment
-----------------
* Biological: Pneumococcal conjugate vaccine GSK 1024850A
* Biological: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female between, and including, 46-50 months of age at the time of vaccination. Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. Subjects who previously participated in study NCT00333450 in centres with more than 2 subjects and received a booster dose of Pneumovax 23™. Written informed consent obtained from both parents/guardians of the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the vaccination, or planned use during the study period. Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination. Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before study vaccination and during the entire study period. Administration of any pneumococcal vaccine since the end of study NCT00333450. Administration of immunoglobulins and/or any blood products less than 3 months prior to the vaccination or planned use during the study period. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical History of any neurologic disorders or seizures Anaphylactic reaction following previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine. History of hypotonic-hyporesponsive episode after any previous vaccination. Major congenital defects or serious chronic illness. History of invasive pneumococcal diseases. Acute disease at the time of vaccination Rectal temperature >= 38.0°C or oral/axillary/tympanic temperature >= 37.5°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.

Ages Eligible for Study
-----------------
Minimum Age: 46 Months
Maximum Age: 50 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pn Group<br>Subjects receiving GSK 1024850A vaccine. | Biological: Pneumococcal conjugate vaccine GSK 1024850A<br>* One dose of vaccine will be injected intramuscularly into the deltoid.<br>|
| Active Comparator: Prev Group<br>Subjects receiving Prevenar™ vaccine. | Biological: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)<br>* One dose of vaccine will be injected intramuscularly into the deltoid.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine Pneumococcal Serotype Antibody Concentrations | The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. | Before (PRE) and one month after (POST) the additional dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes | The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. | Before (PRE) and one month after (POST) the additional dose | 
| Cross-reactive Pneumococcal Serotype Antibody Concentrations | The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A. | Before (PRE) and one month after (POST) the additional dose | 
| Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes | The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A. | Before (PRE) and one month after (POST) the additional dose | 
| Anti-protein D Antibody Concentrations | The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL). | Before (PRE) and one month after (POST) the additional dose | 
| Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Solicited local symptoms assessed include pain, redness, and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger (>) 30 millimeters (mm). Any is defined as incidence of the specified symptom regardless of intensity. | During the 8-day (Days 0-7) post-additional dose | 
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities. Grade 3 loss of appetite was defined as the subject not eating at all. Any is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. | During the 8-day (Days 0-7) post-additional dose | 
| Number of Subjects With Unsolicited Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. | Within 31 days (Day 0-30) post-additional vaccination | 
| Number of Subjects With Serious Adverse Events (SAEs) | An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. | Throughout the entire study period (approximately 1 month per subject) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Haemophilus influenzae, Streptococcus pneumoniae, safety, Pneumococcal conjugate vaccine, immunogenicity